Home › Thyroid Cancer › NCT05229341

Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

Evaluation of DNA Methylation Signatures in Diagnosis and Management of Thyroid Nodules

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patients without impaired decision-making capacity and who are undergoing needle biopsies for thyroid nodule diagnosis
* Over the age of 18
* Any gender, race and ethnicity
* Patients must provide informed consent prior to use of their tissues and clinical data

Exclusion Criteria:

* Children are excluded from the study, since the biology of children thyroid nodules is different from adults

About the study

This clinical trial evaluates deoxyribonucleic acid (DNA) methylation signatures in diagnosing and managing thyroid nodules. The purpose of this research is to develop a new test for thyroid cancer. This test will use needle biopsies (small collections of tissue with a needle) from the thyroid to determine whether the participant has a malignant (cancer) or benign (not showing cancer) thyroid tumor. The information learned from this trial may help develop a more accurate test so that patients do not have unnecessary surgeries for nodules that are thought to be suspicious but are actually benign.

What is being tested

• Diagnostic Procedure (procedure)
• Electronic Health Record Review (other)
• Needle Biopsy (procedure)

Sponsor: City of Hope Medical Center · Participants: 1,450 · Started: Oct 22, 2021

Contact the study team

Official record on ClinicalTrials.gov — NCT05229341

Locations in the U.S.

Conditions

• Thyroid Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.